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Abstract: Gallbladder cancer (GBC) is rare in Western populations and data about treatment and
outcomes are scarce. This study aims to analyze survival and identify opportunities for improvement
using population-based data from a low-incidence country. GBC patients diagnosed between 2005
and 2016 with GBC were identified from the Netherlands Cancer Registry. Patients were grouped
according to time period (2005–2009/2010–2016) and disease stage. Trends in treatment and overall
survival (OS) were analyzed. In total 1834 patients were included: 661 (36%) patients with resected,
278 (15%) with non-resected non-metastatic, and 895 (49%) with metastatic GBC. Use of radical
versus simple cholecystectomy (12% vs. 26%, p < 0.001) in early (pT1b/T2) GBC increased. More
patients with metastatic GBC received chemotherapy (11% vs. 29%, p < 0.001). OS improved from
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4.8 months (2005–2009) to 6.1 months (2010–2016) (p = 0.012). Median OS increased over time
(2005–2009 vs. 2010–2016) in resected (19.4 to 26.8 months, p = 0.038) and metastatic (2.3 vs. 3.4
months, p = 0.001) GBC but not in unresected, non-metastatic GBC. In early GBC, patients with radical
cholecystectomy had a median OS of 76.7 compared to 18.4 months for simple cholecystectomy
(p < 0.001). Palliative chemotherapy showed superior (p < 0.001) survival in metastatic (7.3 versus 2.1
months) and non-resected non-metastatic (7.7 versus 3.5 months) GBC. In conclusion, survival of
GBC remains poor. Radical surgery and palliative chemotherapy appear to improve prognosis but
remain under-utilized.
Keywords: gallbladder neoplasms; cohort studies; chemotherapy; surgery; epidemiology
1. Background
Gallbladder cancer (GBC) is a rare and highly lethal neoplasm of the biliary tract. GBC demonstrates
marked geographic, age-, gender-, and ethnicity-related differences in incidence, implying (epi)genetics
or environmental factors may play an important role in the development of GBC [1–6]. Other possible
risk factors include cholelithiasis, obesity, gallbladder polyps, chronic infections, and an abnormal
pancreaticobiliary duct junction [1,7,8].
Treatment of GBC remains challenging. Diagnosis—unless incidentally after cholecystectomy for
benign gallbladder disease—is often made in an advanced stage and survival is extremely poor due to
the limited efficacy of systemic therapy options [3]. The only treatment with curative intent is surgical
resection. However, due to late detection and a tendency towards invasive local growth, only 10% to
25% of tumors are candidates for potential curative intent surgery at presentation [9,10]. Even after
resection 5-year survival rates are poor, ranging from 12% to 40% in non-incidental tumors [3,11,12].
Long-term survival is only observed in patients with early (T1/T2) GBC, which is mainly diagnosed
incidentally. However, even for these patients, additional radical surgery with resection of the
gallbladder bed and lymph node dissection of the hepatoduodenal ligament is recommended because
it is thought to considerably increase survival [13,14].
The limited benefit of systemic therapy in GBC has been shown in prospective trials; in 2010, the
ABC-02 trial reported a median overall survival (OS) of 11.7 months vs. 8.1 months in unresectable
biliary tract cancer treated with gemcitabine and cisplatin versus gemcitabine alone [15]. This has
since been adopted as the standard regimen in the treatment of unresectable GBC. Although several
randomized clinical trials have investigated the value of adjuvant chemotherapy for biliary tract
cancers, none have found a survival benefit in the intention-to-treat analysis and no adequately
powered subgroup analyses for GBC have been conducted [16,17].
Guidelines for the treatment of localized GBC are mainly based on retrospective evidence and
expert opinion due to the minimal availability of randomized evidence. Previous studies investigating
GBC have typically been conducted in high-volume, non-Western centers and included patients with
various biliary tract cancers [15,18,19]. Due to presumed different etiologies, results in GBC may differ
from those in other biliary tract tumors [20].
Our objective was to investigate trends in treatment, establish prognostic factors associated with
survival and identify opportunities for improvement in treatment stratified for disease stage.
2. Methods
This is a cohort study using data from the nationwide population-based Netherlands Cancer
Registry (NCR), containing information on all newly diagnosed malignancies. The NCR receives
notifications from the automated pathological archive (PALGA), the nation-wide network and registry
of histo- and cytopathology in the Netherlands, and is supplemented by alerts from the National
Archive of Hospital Discharge Diagnosis [21]. Completeness of the registry is estimated to be at least
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95% [22]. Since all data was anonymized a waiver for ethical approval was provided. The STROBE
guidelines for reporting of observational studies have been followed [23]. This study was approved by
the NCR ethical review board and a waiver for ethical approval was provided by the Medical Ethics
Review Committee of the region Arnhem-Nijmegen (CMO A-N, nr. 2017-3912) on 27/12/2017. The
study was conducted according to the Declaration of Helsinki. Anonymized patient level data are
available upon request from the Netherlands Cancer Registry. The statistical code is available upon
request from the corresponding author.
2.1. Patient Selection and Variable Definitions
Clinicopathological data on all adult patients diagnosed between 2005 and 2016 with invasive
gallbladder neoplasms were extracted. The following variables were provided: age, gender, year of
diagnosis, socioeconomic status (social deprivation scores based on a mean number of 4000 inhabitants
per 4-digit postal codes), histopathological or clinical diagnosis, tumor histology (based on the ICD-O3
classification, morphological codes are provided in Appendix A), clinical and pathological TNM stage
(AJCC staging system, version 6 for patients diagnosed from 2005 to 2009 and version 7 from 2010
to 2016 [24,25]), presence and location of metastatic disease, occurrence of syn- or metachronous
primary tumors, type of resection performed, resection margin (R0: microscopically free of tumor,
R1 microscopically positive for tumor, R2: macroscopically positive for tumor), systemic therapy
(yes/no), radiation therapy (yes/no), and duration of follow-up in days from date of diagnosis. Missing
data occurred in four out of nine baseline variables (2% to 29%) and was not imputed because it was
determined not to be missing at random.
Primary radical/extended cholecystectomy was defined as cholecystectomy with en-bloc excision
of the gallbladder bed and dissection of the hepatoduodenal lymph nodes as the first surgery received
by the patient. Re-resection was defined as any surgery for GBC after initial cholecystectomy alone
within 180 days of diagnosis. Radicality was classified into R0 (resection margin microscopically free of
tumor) and R1/2 (resection margin micro- or macroscopically positive). Supportive therapy included
endoscopic procedures, biliary drainage and metastasectomy. Ninety-day mortality was defined as
death within 90 days of diagnosis. Chemo- and radiotherapy were defined as administration of at least
one dose. Information regarding type of systemic therapy received was not available. Follow-up data
on vital status (complete until February 2018) were provided by linkage to the automated Municipal
Personal Records Database.
2.2. Quality Control and Completeness of Data Assessment
Accuracy of diagnosis and completeness of histopathological assessment was assessed by
comparing data from the resected patients provided by the NCR with data extracted from the
medical records available from four academic centers in the Netherlands: Radboudumc, Amsterdam
University Medical Center (location AMC), Erasmus MC and Leiden University Medical Center.
2.3. Statistical Analysis
Characteristics were described using counts and percentages for continuous variables and means
and ranges for continuous variables. χ-square testing or Fisher’s exact test, where appropriate, were
used to assess differences in patient characteristics. Incidence rates were calculated per 100,000 person
years and age-standardized using the European standard population. Trends in incidence were
assessed by calculating the estimated annual percentage change (EAPC).
Patients were grouped according to T-stage (T1/T2 vs. T3/T4), N-stage (N0 vs. N1/N2) and
resection margin (R0 vs. R1/R2 vs. Rx). For survival analyses, patients were categorized as resected,
non-metastatic non-resected (i.e., inoperable patients due to comorbidities and/or locally advanced
disease) or metastatic at diagnosis. To assess trends in treatment over time, patients were grouped
according to period of diagnosis (Period 1; 2005–2009 and Period 2; 2010–2016; these periods coincide
with the introduction of gemcitabine-cisplatin chemotherapy as standard of care for unresected BTC).
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A subgroup analysis in patients with early (T1b/T2) disease was conducted to assess trends in surgical
treatment. Kaplan-Meier curves were used to calculate median OS. OS was defined as time in days
from date of diagnosis until date of death from any cause or the date of last follow-up (February 2018).
Patients alive at the last date of follow-up were censored. Cox regression analysis was used to calculate
hazard ratios for potential prognostic factors. Covariates were selected based on literature and entered
in the multivariable model when statistically relevant (p < 0.1) on univariable analysis. p-values < 0.05
were considered statistically significant. All tests of significance were two-tailed. Statistical analyses
were conducted using the SPSS 24.0 statistical package (SPSS, Inc., Chicago, IL).
3. Results
3.1. Incidence and Patient and Tumor Characteristics
Patient and tumor characteristics are shown in Table 1. Between 2005 and 2016, 1834 patients were
diagnosed with GBC in the Netherlands (Figure 1). Forty-nine percent of patients had metastatic disease
at diagnosis (43% from 2005 to 2009 and 53% from 2010 to 2016, p < 0.001). The incidence of GBC did not
change significantly (EAPC—0.7%, p = 0.32) over time (Appendix B). Median age at diagnosis was 71
(IQR 64–80) years. Eighty percent of patients had histopathological confirmation of diagnosis.
Table 1. Characteristics of patients with gallbladder cancer in the Netherlands (2005–2016).
Cohort Total(n = 1834)
Resected
(n = 661)
Non-resected
Non-metastatic
(n = 278)
Metastatic
(n = 895)
Patient and tumor characteristics
Age 71.1 (22–97) 69.2 (27–97) 74.3 (32–95) 71.2 (22–96)
Male sex 545 (29.1%) 206 (31.2%) 82 (29.5%) 250 (27.9%)
Socioeconomic Status
High 501 (26.8%) 183 (27.7%) 82 (29.5%) 229 (33.4%)
Medium 741 (39.6%) 253 (38.3%) 110 (39.6%) 367 (41.0%)
Low 630 (33.7%) 225 (34.0%) 86 (30.9%) 299 (33.4%)
Clinicopathologic T stage a
T1 526 (28.1%) 147 (22.6%) 1 (0.4%) 54 (8.5%)
T2 303 (45.8%) 0 (0.0%) 22 (2.5%)
T3/T4 643 (34.3%) 172 (26.2%) 169 (60.8%) 427 (47.7%)
TX 496 (26.5%) 38 (5.8%) 13 (4.7%) 302 (33.7%)
Unknown/missing 207 (11.1%) - 95 (34.2%) 90 (10.1%)
Clinicopathologic N stage a
N0 674 (36.0%) 140 (21.2%) 62 (22.3%) 237 (26.5%)
N1 432 (23.1%) 123 (18.6%) 74 (26.6%) 331 (37.0%)
NX 559 (29.9%) 387 (58.5%) 47 (16.9%) 237 (26.5%)
Unknown/missing 207 (11.1%) 11 (1.7%) 95 (34.2%) 90 (10.1%)
Location synchronous metastases
Liver N/A N/A N/A 350 (39.1%)
Peritoneal N/A N/A N/A 119 (13.3%)
Lymph node N/A N/A N/A 46 (5.1%)
Lung N/A N/A N/A 11 (1.2%)
Liver + peritoneum N/A N/A N/A 92 (10.3%)
Other N/A N/A N/A 22 (2.5%)
Multiple, other N/A N/A N/A 175 (19.6%)
Unknown/missing N/A N/A N/A 80 (8.9%)
Pathology confirmation of primary tumor(yes) 1566 (83.7%) 661 (100%) 156 (56.1%) 732 (81.8%)
Differentiation grade
Well N/A 102 (15.4%) N/A N/A
Moderate N/A 209 (31.6%) N/A N/A
Poor N/A 157 (23.7%) N/A N/A
Not determined N/A 193 (29.2%) N/A N/A
Radicality
R0 N/A 417 (63.1%) N/A N/A
R1 N/A 130 (19.7%) N/A N/A
R2 N/A 24 (3.6%) N/A N/A
Unclear N/A 90 (13.6%) N/A N/A
a Clinical P- and N- for unresected patients and pathologic T- and N- stage for resected patients are provided.
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3.2. Treatment
Time trends in treatment in resected, non-resected non-metastatic, and metastatic GBC are shown
in Figure 2. Among all patients with non-metastatic disease, primary resection rates increased; 64.7% in
2005 to 2009 to 74.8% in 2010 to 2016 (p = 0.001). More extensive tumors (T3–T4) were resected between
2010 and 2016 compared to 2009 to 2015 (from 25.1% to 33.1%, p < 0.001). In resected, non-metastatic
patients, 90-day mortality decreased from 12.0% to 5.6% (p = 0.003) and the percentage of patients
receiving R0 resecti d d not change significantly (from 70.3% to 74.7%, p = 0.294). The number of
patients receiving an extended cholecystectomy (with/without hepatoduodenal lymphadenectomy)
opposed to simple cholecystectomy in early (T1b–T2) GBC increased significantly, from 19% to 33% (p
< 0.001). In the subgroup analysis conducted in patients with early GBC, 90-day mortality and the R0
resection rate did not change over time. Adjuvant chemotherapy was only administered to 12/661
(1.8%) patients.
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Use of palliative chemotherapy did not increase in patients with unresected, non-metastatic GBC
(15% vs. 15%, Figure 2). The use of palliative chemotherapy in metastatic GBC increased from 11% to
29% (p < 0.001).
3.3. Survival
Median OS of the entire cohort was 5.5 months (95% CI 5.0–6.0) and increased from 4.8 months
(95% CI 4.2–5.4) in 2005 to 2009 to 6.1 months (95% CI 5.4–6.8) in 2010 to 2016 (p = 0.012) (Figure 3A).
Median OS differed significantly between resected and non-metastatic non-resected/metastatic disease:
23.7 (95% CI 19.6–27.8), 3.6 (95% CI 3.1–4.6) and 2.7 (95% CI 2.6–3.2) months, respectively (p < 0.001,
Figure 3B). Resected patients showed improved median OS over time; from 19.4 to 26.8 months (p
= 0.038, Appendix C). Median OS in metastatic patients increased from 2.3 to 3.4 months (p < 0.001,
Appendix C). In non-resected patients survival did not change significantly over time.
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3.4. Therapy and Survival
Survival in patient groups with resected, non-metastatic non-resected and metastatic GBC is
shown in Table 2. The survival benefit of adjuvant chemotherapy could not be assessed since only 12
out of 661 patients received some form of adjuvant therapy. R dical su gery (either primary radical
cholecystectomy or re-resection) in arly GBC was associated with a significantly higher median OS
compared to simple cholecystecto y, ro 18.4 to 76.7 months (p < 0.001). Palliative chemotherapy in
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non-resected non-metastatic and metastatic disease was associated with superior survival; from 3.5 to
7.7 (p = 0.011) and 2.1 versus 7.3 (p < 0.001) months, respectively.
Table 2. Survival of patients with gallbladder cancer according to clinical stage and treatment strategy.
Group N Five-year Survival Median OS, Months (95% CI) Log Rank Test p Value
Total 1895 13.2% 5.5 (5.0–6.0)
Resected non-metastatic 661 34.2% 23.7 (19.6–27.8)
Adjuvant chemotherapy 12 37.5% 29.4 (21.4–37.5)
0.521
No adjuvant chemotherapy 649 34.1% 23.7 (19.4–27.6)
T1b/T2 tumor, no radical surgery 106 30.6% 18.3 (13.8–22.7)
<0.001
T1b/T2 tumor, radical surgery 274 52.7% 76.7 (43.0–110.3)
Non-resected non-metastatic 278 2.9% 3.6 (3.1–4.1)
No palliative chemotherapy 257 3.0% 3.5 (2.9–4.0)
0.011
Palliative chemotherapy 21 - 7.7 (4.5–10.8
Metastatic 895 1.3% 2.9 (2.6–3.2)
No palliative chemotherapy 690 0.6% 2.1 (1.9–2.4)
<0.001
Palliative chemotherapy 205 3.7% 7.3 (6.4–8.2)
3.5. Prognostic Factors for Survival
Poor prognostic factors were increasing age, poor tumor differentiation, higher T-stage, presence
of lymph node metastases and (in resected patients) non-radical resection Table 3.
Table 3. Prognostic factors for patients with resected (A) and metastatic (B) gallbladder cancer.
A. Prognostic factors for patients with resected gallbladder cancer. N = 661.
Characteristic
Univariable Cox Regression Multivariable Cox Regression
HR 95% CI p Value HR 95% CI p Value
Grade
Well 1 1
Moderate 1.41 1.02–1.95 0.036 1.17 0.84–1.61 0.354
Poor 2.67 1.93–3.70 <0.001 2.07 1.49–2.86 <0.001
Unknown 1.45 1.05–1.99 0.023 1.74 1.26–2.41 0.001
Sex
Female 1
Male 0.88 0.71–1.08 0.214
Pathological T stage
T1 1 1
T2 1.77 1.35–2.32 <0.001 1.58 1.19–2.10 0.001
T3/T4 3.59 2.69–4.78 <0.001 2.61 1.89–3.61 <0.001
Tx 3.23 2.01–5.18 <0.001 2.16 1.34–3.50 0.002
Pathological N stage
N0 1 1
N1 2.96 2.13–4.12 <0.001 1.95 1.39–2.74 <0.001
Nx 2.48 1.86–3.31 <0.001 1.86 1.46–2.66 <0.001
Radicality
R0 1 1
R1/R2 3.78 3.03–4.71 <0.001 2.69 2.11–3.43 <0.001
Unclear 1.60 1.20–2.14 0.001 1.48 1.10–1.98 0.009
Adjuvant chemotherapy (yes) 0.67 0.33–1.36 0.268
Prior malignancy (yes) 1.22 0.93–1.61 0.150
Increasing age (years) 1.04 1.03–1.05 <0.001 1.04 1.03–1.05 <0.001
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Table 3. Cont.
B. Prognostic factors for patients with metastatic gallbladder cancer. N = 895.
Characteristic
Univariable Cox Regression Multivariable Cox Regression
HR 95% CI p Value HR 95% CI p Value
Grade
Well 1
Moderately 1.02 0.61–1.71 0.931
Poor 1.45 0.89–2.36 0.136
Unknown 1.85 1.16–2.97 0.010
Sex
Female 1
Male 0.88 0.71–1.08 0.214
Clinical T stage
T1/T2 1 1
T3/T4 2.01 1.57–2.58 <0.001 1.33 1.02–1.73 0.036
Tx 1.82 1.41–2.35 <0.001 1.33 1.02–1.74 0.035
Unknown 3.94 2.88–5.39 <0.001 2.22 1.57–3.15 <0.001
Clinical N stage
N0 1 1
N1 1.28 1.07–1.50 0.006 1.21 1.02–1.44 0.031
Nx 1.50 1.25–1.80 <0.001 1.54 1.28–1.86 <0.001
Unknown 2.70 2.11–3.47 <0.001 **
Supportive therapy (yes) 1.07 0.90–1.27 0.443
Palliative chemotherapy (yes) 0.46 0.39–0.54 <0.001 0.47 0.39–0.55 <0.001
Prior malignancy (yes) 0.93 0.80–1.08 0.358
Increasing age (year) 1.03 1.03–1.04 <0.001 1.02 1.01–1.03 <0.001
** Removed due to collinearity.
Palliative surgery and chemotherapy were associated with a better prognosis in metastatic disease
(HR 0.43 and 0.47 respectively, p < 0.001).
3.6. Quality Control
In total, 108 patients (16% of resected patients) underwent a resection in one of the four academic
hospitals. One patient (0.9%) turned out to have cholecystitis and was incorrectly registered by the
NCR as having GBC.
4. Discussion
Between 2000 and 2016, no (clinically) significant changes in incidence and survival of GBC
were seen. Although radical surgery in early GBC and palliative chemotherapy in unresectable and
metastatic GBC significantly improved survival, these treatment modalities were only used in 33%
(radical surgery) and 25% (palliative chemotherapy) of patients.
The survival rates as demonstrated in this study are comparable to those from a previously
published Western cohorts [26,27], but inferior to survival rates from non-Western centers: three-year
survival was 73% for stage I (53% in stage II) in our study compared to 100% (80% in stage II) in a
recently conducted Korean study including 142 patients [28]. These differences are possibly attributable
to selection bias in high-volume expert centers in non-Western countries, different tumor biology or
differences in the administration of adjuvant chemotherapy, which has not been standard practice in
the Netherlands [29].
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In a subgroup analysis, improved survival over time was only seen in resected and metastatic
GBC. The improved outcome of resected patients is likely the result of multiple factors. Although
primary resection rates remained stable, larger tumors (T3/T4) were increasingly resected and 90-day
mortality decreased significantly over time, suggesting an improvement in operative techniques or
postoperative care. A sharp increase in re-resection rates for early GBC was seen after 2010, coinciding
with a change in national guidelines advocating for the use of additional gallbladder bed resection and
regional lymphadenectomy in early (pT1b/T2) GBC, which is associated with significantly improved
outcomes [14,30–33]. Our results support this notion; patients with early GBC who received radical
surgery had a median OS that was over three times larger (76.7 vs. 18.4 months) than the survival of
patients who did not undergo radical resection.
Unfortunately, our results suggest substantial undertreatment; even during the last study period
only 33% of patients with early-stage GBC received the recommended radical surgery in addition to
cholecystectomy alone. Most likely, the majority of the early GBC patients are diagnosed incidentally
after cholecystectomy for suspected benign gallbladder disease by a general gastrointestinal surgeon
in a community hospital. We hypothesize that many clinicians still perceive advanced GBC as an
untreatable disease and thus may be reluctant to refer patients to a specialized hepatobiliary center for
additional surgery or chemotherapy. We believe that multidisciplinary, specialized care, and better
adherence to (inter-)national guidelines may improve prognosis of GBC patients.
Previous studies show conflicting results on the value of adjuvant chemotherapy. Most evidence
is based on small, retrospective series and only one recently published phase-3 trial showed a survival
benefit in the per-protocol analysis alone [17]. Currently, recruiting large, prospective trials may show
more positive results [34]. Unfortunately, the effect of adjuvant therapy after resection could not
be assessed as adjuvant therapy is currently not standard of care in the Netherlands and was only
administered to a small number of cases (most likely in a clinical trial setting).
In 2010, the ABC-02 trial demonstrated a survival benefit of gemcitabine and cisplatin in metastatic
biliary tract cancer [15], resulting in an update of the national guidelines and palliative chemotherapy
becoming standard of care. Although a subsequent rise from 15% to 25% in the use of palliative
chemotherapy was seen after 2010, it was still infrequently administered. Since (subsidized) healthcare
insurance is mandatory for all inhabitants of the Netherlands and travel distance to healthcare is
generally short, the most likely explanation for this poor delivery rate is nihilism regarding the efficacy
of chemotherapy. Evidently, chemotherapy in non-resectable GBC warrants further attention since the
increase in use of palliative chemotherapy is a likely cause for the (minor) improvement in median OS
in metastatic GBC.
The major limitation of this study pertains to the nature of registration data; because of the
retrospective nature of this study, selection bias is present. Caution should be exercised when
interpreting results, especially when analyzing treatment strategies and associated differences in
survival. Additionally, possible incompleteness of data in the earlier years and changes in registry
guidelines resulted in missing data on prognostic factors such as T- and N-stage (16%) in unresected
patients and tumor grade (29%) in resected patients.
Second, distinguishing GBC from perihilar cholangiocarcinoma (proximal extrahepatic
cholangiocarcinoma, pCC) is challenging in locally advanced disease [35]. Diagnosis in unresected
patients was based on imaging only and histopathological confirmation was available in 76% of patients.
However, recent research highlights the importance of this distinction, as GBC and pCC show different
molecular landscapes and consequently might benefit from different treatment options [20,36,37].
The results from this study reflect current clinical practice until more reliable diagnostic methods to
differentiate between GBC and pCC become available.
A unique strength of this study is the nation-wide, population based design resulting in an
accurate representation of treatment and survival patterns of gallbladder cancer in daily clinical
practice in a low incidence population. In addition, we were able to perform a quality control and
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demonstrated that the accuracy of the registration data is very high, since only 1 out of 108 patients
received an incorrect diagnosis.
5. Conclusions
In conclusion, survival of GBC is poor and minimal improvement has been made in the past
decade in the Netherlands. Radical surgery in early GBC and palliative chemotherapy in unresectable
and metastatic GBC are associated with increased OS. However, the use of these treatment modalities
is still limited. A multidisciplinary approach in GBC involving radical surgery and systemic therapy
may lead to improvement in the survival of GBC patients.
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Appendix A.
ICD-03 code Frequency (%)
8000 Neoplasma 310 (16.6)
8001 Tumor cells 2 (0.1)
8010 Carcinoma, NOS 50 (2.7)
8012 Large cell carcinoma NOS 35 (1.9)
8013 Large cell neuroendocrine carcinoma 6 (0.3)
8020 Carcinoma, undifferentiated, NOS 5 (0.3)
8030 Giant cell and spindle cell carcinoma 2 (0.1)
8032 Spindle cell carcinoma, NOS 2 (0.1)
8033 Pseudosarcomatous carcinoma 3 (0.2)
8041 Small cell carcinoma, NOS 10 (0.5)
8046 Non-small cell carcinoma 4 (0.2)
8070 Squamous cell carcinoma, NOS 19 (1.0)
8071 Squamous cell carcinoma, keratinizing, NOS 2 (0.1)
8074 Squamous cell carcinoma, spindle cell 1 (0.1)
8140 Adenocarcinoma, NOS 1171 (62.6)
8144 Adenocarcinoma, intestinal type 21 (1.1)
8160 Cholangiocarcinoma 6 (0.3)
8163 Pancreatobiliary-type carcinoma 5 (0.3)
8210 Adenocarcinoma in adenomatous polyp 7 (0.4)
8211 Tubular adenocarcinoma 2 (0.1)
8240 Carcinoid tumor, NOS 13 (0.7)
8244 Mixed adenoneuroendocrine carcinoma 2 (0.1)
8246 Neuroendocrine carcinoma, NOS 6 (0.3)
8249 Atypical carcinoid tumor 2 (0.1)
8260 Papillary adenocarcinoma, NOS 36 (1.9)
8263 Adenocarcinoma in tubolovillous adenoma 3 (0.2)
8310 Clear cell adenocarcinoma, NOS 3 (0.2)
8312 Renal cell carcinoma, NOS 1 (0.1)
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8350 Nonencapsulated sclerosing carcinoma 1 (0.1)
8480 Mucinous adenocarcinoma 31 (1.7)
8481 Mucin-producing adenocarcinoma 44 (2.4)
8490 Signet ring cell carcinoma 19 (1.0)
8500 Infiltrating duct carcinoma, NOS 2 (0.1)
8503 Intraductal papillary adenocarcinoma with invasion 4 (0.2)
8560 Adenosquamous carcinoma 26 (1.4)
8570 Adenocarcinoma with squamous metaplasia 1 (0.1)
8574 Adenocarcinoma with neuroendocrine differentiation 10 (0.5)
8575 Metaplastic carcinoma, NOS 1 (0.1)
8576 Hepatoid adenocarcinoma 1 (0.1)
8980 Carcinosarcoma, NOS 3 (0.2)
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